Corcept Therapeutics | CORT - Operating Profit


Corcept Therapeutics reported $114.72M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Alaunos Therapeutics USD -952K 60K Jun/2026
ANI Pharmaceuticals USD 51.84M 12M Sep/2026
Ardelyx USD -12.42M 20.37M Jun/2026
Aurora Cannabis CAD -8.73M 1.3M Jun/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Canopy Growth CAD -17.58M 9.9M Jun/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
J&J USD 6.47B 1B Sep/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Merck USD 7.33B 6.49B Sep/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 5.14B 392M Sep/2026
Novartis USD 1.84B 2.39B Sep/2026
Omeros USD -35.41M 23.75M Sep/2024
Pacira USD 2.57B 2.56B Sep/2026
Pfizer USD 662M 5M Sep/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
TG Therapeutics USD 21.67M 13.12M Jun/2026